Literature DB >> 9987156

Studies on the structures and antigenic properties of rabies virus glycoprotein analogues produced in yeast cells.

S Sakamoto1, T Ide, S Tokiyoshi, J Nakao, F Hamada, M Yamamoto, J A Grosby, Y Ni, A Kawai.   

Abstract

We investigated two forms (designated as yGI and yGII) of rabies virus glycoprotein (G) analogues produced in the G cDNA-transfected yeast cells. Molecular weights of yGI and yGII were estimated as 66 and 56 kDa, respectively, according to their relative mobility in SDS-PAGE. Although being produced in large amounts, yGI was present mostly in insoluble forms and hardly extractable with non-ionic detergents. The yGI reacted with polyclonal anti-G antibodies, but did not react with our conformational epitope-specific anti-G monoclonal antibodies (G-MAbs). No protective immunity was induced by yGI in guinea pigs nor in mice. On the other hand, yGII was Triton-soluble, but was only small in amount (at most 1% of total G proteins) and was shown to lack the cytoplasmic domain. The yGII, however, reacted with the G-MAbs and induced protective immunity in guinea pigs as well. When the G-cDNA was expressed in animal cells in culture, a single form (about 66 kDa) of G protein was produced, which displayed similar behaviors as seen in its reactivity with the MAbs and intracellular distribution as seen in the virus-infected cells. These results suggest that most G protein molecules were not processed normally in yeast cells, resulting in abnormal folding and multimer formation, while only a small fraction were occasionally folded normally to have conformational epitopes but were mostly deprived of the C-terminal portion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9987156     DOI: 10.1016/s0264-410x(98)00196-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Enhanced production of recombinant rabies virus glycoprotein (rRVGP) by Drosophila melanogaster S2 cells through control of culture conditions.

Authors:  Kamilla Swiech; Nickeli Rossi; Renato M Astray; Cláudio A T Suazo
Journal:  Cytotechnology       Date:  2008-02-24       Impact factor: 2.058

2.  Expression and solubilization of insect cell-based rabies virus glycoprotein and assessment of its immunogenicity and protective efficacy in mice.

Authors:  R Ramya; B Mohana Subramanian; V Sivakumar; R L Senthilkumar; K R S Sambasiva Rao; V A Srinivasan
Journal:  Clin Vaccine Immunol       Date:  2011-08-03

Review 3.  Current Developments and Future Prospects for Plant-Made Biopharmaceuticals Against Rabies.

Authors:  Sergio Rosales-Mendoza
Journal:  Mol Biotechnol       Date:  2015-10       Impact factor: 2.695

4.  Highly efficient production of rabies virus glycoprotein G ectodomain in Sf9 insect cells.

Authors:  Alexandra Marisa Targovnik; Alejandro Ferrari; Gregorio Juan Mc Callum; Mariana Bernadett Arregui; Ignacio Smith; Lautaro Fidel Bracco; Victoria Alfonso; María Gabriela López; María Martínez-Solís; Salvador Herrero; María Victoria Miranda
Journal:  3 Biotech       Date:  2019-10-04       Impact factor: 2.406

5.  Secretion of truncated recombinant rabies virus glycoprotein with preserved antigenic properties using a co-expression system in Hansenula polymorpha.

Authors:  Weidong Qian; Frank Aguilar; Ting Wang; Bingsheng Qiu
Journal:  J Microbiol       Date:  2013-04-27       Impact factor: 3.422

Review 6.  Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses.

Authors:  Venice Du Pont; Richard K Plemper; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2019-02-10       Impact factor: 7.090

7.  Overexpression of human virus surface glycoprotein precursors induces cytosolic unfolded protein response in Saccharomyces cerevisiae.

Authors:  Evaldas Ciplys; Dhanraj Samuel; Mindaugas Juozapaitis; Kęstutis Sasnauskas; Rimantas Slibinskas
Journal:  Microb Cell Fact       Date:  2011-05-19       Impact factor: 5.328

Review 8.  Rabies Control and Treatment: From Prophylaxis to Strategies with Curative Potential.

Authors:  Shimao Zhu; Caiping Guo
Journal:  Viruses       Date:  2016-10-28       Impact factor: 5.048

9.  Novel vaccines to human rabies.

Authors:  Hildegund C J Ertl
Journal:  PLoS Negl Trop Dis       Date:  2009-09-29

10.  The use of chimeric virus-like particles harbouring a segment of hantavirus Gc glycoprotein to generate a broadly-reactive hantavirus-specific monoclonal antibody.

Authors:  Aurelija Zvirbliene; Indre Kucinskaite-Kodze; Ausra Razanskiene; Rasa Petraityte-Burneikiene; Boris Klempa; Rainer G Ulrich; Alma Gedvilaite
Journal:  Viruses       Date:  2014-02-07       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.